Ketamine Therapy (Spravato)
For Treatment Resistant Depression
Spravato (Esketamine) is the first novel antidepressant introduced in over three decades. It was FDA approved for Treatment Resistant Depression (TRD) in March of 2019.
SPRAVATO™ nasal spray is a different kind of medication taken with an oral antidepressant for adults with treatment-resistant depression – a first in decades approved by the FDA.
If you’ve struggled with depression and tried two or more antidepressants* in your current episode without adequate relief, talk to your doctor to see if you have treatment-resistant depression.
*Of adequate dose and duration.
SPRAVATO™ is also used to treat:
• Social anxiety disorder
• Refractory anxiety
• Anxiety in adolescents
This medication is to be used in conjunction with an oral antidepressant. Spravato is administered by the patient in the doctor’s office via intranasal route. The induction phase consist of twice weekly treatment fo weeks 1-5, then once weekly for weeks 5-8, then weekly or biweekly thereafter for the remainder of the year. Some insurance companies have already started to approve the medication for TRD and in some cases Janssen, the drug producer, can help assist you with the approval process. Patient will be instructed to have no food or liquids 30 minutes prior to administration of Spravato and the doctor or assistant will observe for two hours for post administration monitoring.